Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors?

Treatment of cancer has transformed with the introduction of checkpoint inhibitors. However, the majority of solid tumor patients do not respond to checkpoint blockade. In contrast, the response rate to programmed cell death 1 (PD-1) blockade in relapsed/refractory classical Hodgkin lymphoma (cHL) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Ah-Reum, Ball, Edward D, Goodman, Aaron Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780174/
https://www.ncbi.nlm.nih.gov/pubmed/33447123
http://dx.doi.org/10.1177/1179554920976366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780174/
https://www.ncbi.nlm.nih.gov/pubmed/33447123
http://dx.doi.org/10.1177/1179554920976366

Ejemplares similares